Optimal Interval for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Stable Infliximab Maintenance Treatment

被引：0
|
作者：
Hong, S. N. [1 ]
Yujin, L. [1 ]
Boram, P. [2 ]
Soon, J. Ok [3 ]
Ho, K. Young [1 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Dept Med, Samsung Med Ctr, Seoul, South Korea
[2] Samsung Med Ctr, Biomed Stat Ctr, Res Inst Future Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Dept Data Serv Team, Samsung Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P353
引用
收藏
页码：I745 / I745
页数：1
相关论文
共 50 条
  • [21] Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease
    Gibson, David J.
    Ward, Mark G.
    Rentsch, Clarissa
    Friedman, Antony B.
    Taylor, Kirstin M.
    Sparrow, Miles P.
    Gibson, Peter R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (06) : 612 - 628
  • [22] Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment-TUMMY Study
    Sivridas, Merve
    Creemers, Rob H.
    Wong, Dennis R.
    Boekema, Paul J.
    Romkens, Tessa E. H.
    Gilissen, Lennard P. L.
    van Bodegraven, Adriaan A.
    Loeff, Floris C.
    Rispens, Theo
    Derijks, Luc J. J.
    PHARMACEUTICS, 2023, 15 (03)
  • [23] New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases
    Nemoz, Benjamin
    Ternant, David
    Bailly, Sebastien
    Gautier-Veyret, Elodie
    Jourdil, Jean-Francois
    Bonaz, Bruno
    Stanke-Labesque, Francoise
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (04) : 722 - 728
  • [24] Proactive therapeutic drug monitoring (TDM) of infliximab leads to durability of treatment in children with inflammatory bowel disease
    Chuah, Cher Wei
    Dutt, Shoma
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 325 - 325
  • [25] Predictive Model for Outcomes in Inflammatory Bowel Disease Patients Receiving Maintenance Infliximab Therapy
    Wong, Rochelle
    Charilaou, Paris
    Hemperly, Amy
    Qin, Lihui
    Pan, Yushan
    Mathani, Prerna
    Longman, Randy
    Boland, Brigid S.
    Dulai, Parambir S.
    Holmer, Ariela K.
    Lukin, Dana
    Singh, Siddharth
    Valasek, Mark A.
    Sandborn, William J.
    Scherl, Ellen
    Vande Casteele, Niels
    Battat, Robert
    CROHNS & COLITIS 360, 2024, 6 (04)
  • [26] Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease
    Deora, Vini
    Kozak, Justin
    El-Kalla, Mohamed
    Huynh, Hien Q.
    El-Matary, Wael
    ACTA PAEDIATRICA, 2017, 106 (11) : 1863 - 1867
  • [27] Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study
    Paul, Stephane
    Del Tedesco, Emilie
    Marotte, Hubert
    Rinaudo-Gaujous, Melanie
    Moreau, Amelie
    Phelip, Jean-Marc
    Genin, Christian
    Peyrin-Biroulet, Laurent
    Roblin, Xavier
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (12) : 2568 - 2576
  • [28] THE IMPACT OF THERAPEUTIC DRUG MONITORING DURING BIOSIMILAR INFLIXIMAB SWITCH IN INFLAMMATORY BOWEL DISEASE
    Ranjan, Ravi
    Myers, Sally
    Crissop, Linda
    Ritchie, Susan
    Maw, Frances
    Sebastian, Shaji
    Dhar, Anjan
    GUT, 2018, 67 : A74 - A74
  • [29] The impact of therapeutic drug monitoring during biosimilar infliximab switch in inflammatory bowel disease
    Ranjan, R.
    Myers, S.
    Crissop, L.
    Ritchie, S.
    Maw, F.
    Sebastian, S.
    Dhar, A.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S335 - S335
  • [30] Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease
    Kolho, Kaija-Leena
    FRONTIERS IN PEDIATRICS, 2021, 8
12345